Mission Bio and S2 Genomics to Provide Tumor Sample for Single-cell DNA Analysis

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), validated the automated nuclei workflow, which she presented at the American Association for Cancer Research (AACR) Annual Meeting last week.

Single-cell DNA analysis has revolutionized cancer research, allowing researchers to gain high-resolution insights into tumor heterogeneity, leading to a slew of high-profile papers on disease causes. Solid tumor profiling, on the other hand, presents significant problems, as existing prep procedures sometimes fail to yield enough cells or nuclei to offer relevant data.

Mission Bio introduced their Tapestri Solution for Solid Tumor Research last month to address this issue, which includes new pre-designed research panels for breast cancer and glioblastoma multiforme, as well as an upgraded single-cell copy number variation (CNV) bioinformatic analysis tool. S2 Genomics' SingulatorTM 100 technology for automated dissociation of solid tissue into single-cell or nuclei suspensions can now be used in conjunction with Tapestri to achieve scalable, high-yield, efficient, and repeatable tissue processing.

We are eager to partner with leading companies to address key challenges to sample prep in solid tumor research, As Dr. Iacobuzio-Donahue's lab demonstrates, the Singulator 100 and Tapestri together are a powerful solution enabling single-cell DNA sequencing at scale, in pancreatic cancer research and across a variety of tissue types."

The Singulator 100 has been an important tool for enabling single-cell sequencing in solid tissue, but cancer researchers have been unable to directly interrogate DNA, Tapestri is the only commercial platform capable of single-cell DNA analysis, and we're excited to offer this single automated pipeline connecting cell and nuclei prep to Tapestri's microfluidics-based workflow."

John Bashkin, Chief Strategy Officer of S2 Genomics.